Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.52 |
| ▸ | METAP2 | P50579 | 7/20 | 0.52 |
| ▸ | METAP1 | P53582 | 7/20 | 0.52 |
| ▸ | CTSK | P43235 | 6/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.47 |
| ▸ | ACER2 | Q5QJU3 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 2/20 | 0.47 |
| ▸ | MMP3 | P08254 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8372763 | 1.00 | POLB (0.68) | POLBMEN1KMT2ACTDSP1METAP2 | |
| SCHEMBL4810725 | 1.00 | POLB (0.68) | POLBMEN1KMT2ACTDSP1METAP2 | |
| SCHEMBL8372762 | 1.00 | POLB (0.68) | POLBMEN1KMT2ACTDSP1METAP2 | |
| SCHEMBL418739 | 0.92 | POLB (0.59) | POLBMEN1KMT2ACTDSP1METAP2 | |
| SCHEMBL417597 | 0.92 | POLB (0.59) | POLBMEN1KMT2ACTDSP1METAP2 | |
| SCHEMBL13643823 | 0.86 | MEN1 (0.65) | POLBMEN1KMT2ACTDSP1METAP2 | |
| SCHEMBL5639478 | 0.83 | POLB (0.67) | POLBMEN1KMT2ACTDSP1CTSK | |
| SCHEMBL4820530 | 0.83 | POLB (0.67) | POLBMEN1KMT2ACTDSP1CTSK | |
| SCHEMBL4820525 | 0.83 | POLB (0.67) | POLBMEN1KMT2ACTDSP1CTSK | |
| SCHEMBL8354345 | 0.82 | EPHX2 (0.50) | POLBMEN1KMT2ACTDSP1METAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7402606-B2 | Derivatives of 1-(oxoaminoacetyl) pentylcarbamate as cathepsin K inhibitors for the treatment of bone loss | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-22 | — | — | US | disclosed |
| US-20050245596-A1 | Derivatives of 1-(oxoaminoacetyl) pentylcarbamate as cathepsin k inhibitors for the treatment of bone loss | SMITHKLINE BEECHAM CORPORATION | 2005-11-03 | — | — | US | disclosed |
| EP-1494663-A1 | DERIVATIVES OF 1-(OXOAMINOACETYL) PENTYLCARBAMATE AS CATHEPSIN K INHIBITORS FOR THE TREATMENT OF BONE LOSS | SmithKline Beecham Corporation (US) | 2005-01-12 | — | — | EP | disclosed |
| WO-2003086385-A1 | DERIVATIVES OF 1-(OXOAMINOACETYL) PENTYLCARBAMATE AS CATHEPSIN K INHIBITORS FOR THE TREATMENT OF BONE LOSS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245596-A1 | Derivatives of 1-(oxoaminoacetyl) pentylcarbamate as cathepsin k inhibitors for the treatment of bone loss | CTSK, CTSB, CTSD | POLB 2563/4885MEN1 3686/4885KMT2A 964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.